{
    "2020-09-18": [
        [
            {
                "time": "2020-01-01",
                "original_text": "Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments",
                "features": {
                    "keywords": [
                        "clinical trials",
                        "arthritis drugs",
                        "COVID-19 treatments"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "Why Pfizer Is Seriously Mispriced",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "mispriced"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "Sorrento Gets FDA Nod for Phase I Study on Coronavirus Antibody",
                "features": {
                    "keywords": [
                        "Sorrento",
                        "FDA",
                        "Phase I",
                        "Coronavirus Antibody"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "Lilly, Amgen Ink Manufacturing Deal for Coronavirus Antibodies",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Amgen",
                        "Manufacturing Deal",
                        "Coronavirus Antibodies"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals",
                "features": {
                    "keywords": [
                        "AZN",
                        "LLY",
                        "PFE",
                        "MRK",
                        "Coronavirus Updates",
                        "Cancer Deals"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "Coronavirus update: Global case tally tops 30 million, and controversial CDC testing guideline changes were reportedly not made by CDC scientists",
                "features": {
                    "keywords": [
                        "Coronavirus",
                        "Global case tally",
                        "CDC",
                        "testing guideline changes"
                    ],
                    "sentiment_score": -0.4,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "public health"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "A Look Into Eli Lilly's Debt",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Debt"
                    ],
                    "sentiment_score": -0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-01-01",
                "original_text": "CHMP Recommends Approval of Lilly's Baricitinib for the Treatment of Adults with Moderate to Severe Atopic Dermatitis",
                "features": {
                    "keywords": [
                        "CHMP",
                        "Approval",
                        "Lilly",
                        "Baricitinib",
                        "Atopic Dermatitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}